10.06.2022 - - As of the data cutoff date of 29 April 2022, in addition to improvements in the standard metrics of spleen volume reduction and symptom scores, long term treatment with bomedemstat showed: 52% had reductions in mutant allele frequencies, . Seite 1
– MOMENTUM data demonstrate potential use of momelotinib in myelofibrosis patients who are symptomatic and anemic –
– Additional data highlight improved transfusion independence,. | May 26, 2022